Arkansas alleges insulin pricing plot involving Novo Nordisk, Eli Lilly and Sanofi

Arkansas Attorney General Leslie Rutledge has filed a complaint alleging that the insulin makers have colluded with a group of pharmacy benefit managers, including Express Scripts, to raise insulin prices and pay back the PBMs in discounts.

Arkansas Attorney General Leslie Rutledge | Photo: Staci R. Vandagriff/AP/Ritzau Scanpix

The State of Arkansas has filed a complaint against Novo Nordisk, Eli Lilly, and Sanofi – all makers of the insulin supplying the state – as well as a group of pharmacy benefit managers (PBMs) that dominate the insulin pricing system there, including Express Scripts, which is the biggest PBM in the US.

According to Endpoints News, Arkansas Attorney General Leslie Rutledge is claiming that these two groups have devised a scheme where the insulin makers raise their drug prices artificially and then pay some of the profits to the PBMs in rebates.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs